Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis
Claudia Günther, … , Christoph Becker, Stefan Wirtz
Claudia Günther, … , Christoph Becker, Stefan Wirtz
Published October 17, 2016
Citation Information: J Clin Invest. 2016;126(11):4346-4360. https://doi.org/10.1172/JCI87545.
View: Text | PDF
Research Article Autoimmunity

The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis

  • Text
  • PDF
Abstract

Although necrosis and necroinflammation are central features of many liver diseases, the role of programmed necrosis in the context of inflammation-dependent hepatocellular death remains to be fully determined. Here, we have demonstrated that the pseudokinase mixed lineage kinase domain–like protein (MLKL), which plays a key role in the execution of receptor-interacting protein (RIP) kinase–dependent necroptosis, is upregulated and activated in human autoimmune hepatitis and in a murine model of inflammation-dependent hepatitis. Using genetic and pharmacologic approaches, we determined that hepatocellular necrosis in experimental hepatitis is driven by an MLKL-dependent pathway that occurs independently of RIPK3. Moreover, we have provided evidence that the cytotoxic activity of the proinflammatory cytokine IFN-γ in hepatic inflammation is strongly connected to induction of MLKL expression via activation of the transcription factor STAT1. In summary, our results reveal a pathway for MLKL-dependent programmed necrosis that is executed in the absence of RIPK3 and potentially drives the pathogenesis of severe liver diseases.

Authors

Claudia Günther, Gui-Wei He, Andreas E. Kremer, James M. Murphy, Emma J. Petrie, Kerstin Amann, Peter Vandenabeele, Andreas Linkermann, Christopher Poremba, Ulrike Schleicher, Christin Dewitz, Stefan Krautwald, Markus F. Neurath, Christoph Becker, Stefan Wirtz

×

Figure 6

RIPK3 is dispensable for ConA-induced hepatic injury.

Options: View larger image (or click on image) Download as PowerPoint
RIPK3 is dispensable for ConA-induced hepatic injury.
C57BL/6 and Ripk3–...
C57BL/6 and Ripk3–/– mice were i.v. injected with ConA and analyzed 7 hours later. Experiments were repeated 3 times with similar results. (A) Representative images of liver tissue sections double stained for RIPK3 and β-catenin (confocal images are on the right; the dashed line separates necrotic areas from nonnecrotic areas; arrows demonstrate RIPK3-positive immune cells; asterisks mark representative hepatocytes). (B) Plasma AST concentrations of ConA-challenged control and Ripk3–/– mice (n > 3 per group) and evaluation of necrotic areas in TUNEL assay–stained liver sections of control and Ripk3–/– mice (from C, n > 3 per group). (C) Representative images of immunohistochemical (TUNEL assay) staining analysis of hepatic tissue sections. (D) Representative images of MLKL-stained liver tissue sections. (E) Quantification of plasma membrane localized MLKL (from D, n > 4 per group). (F) Western Blot analysis demonstrating that endogenous MLKL locates at the plasma membrane (PM) in Ripk3–/– mice following ConA treatment. C; cytoplasm. (G) Endogenous MLKL was immunoprecipitated with anti-MLKL antibody in lysates of L929 cells (treated for 3 hours with TNF-α/zVAD/SMAC mimetic) or in liver lysates of ConA-challenged wild-type or Ripk3–/– mice. (H) Recombinant hRIPK3, but not hRIPK1, kinase domain undergoes autophosphorylation and can mediate hMLKL phosphorylation in vitro. Phosphoryl transfer of 32P by 25 ng/μl hRIPK1 or hRIPK3 kinase domain in the absence of hMLKL, or 75 ng/μl hMLKL in the absence of kinase, or 2.5 ng/μl hRIPK1 or hRIPK3 in the presence of 75 ng/μl hMLKL was detected by autoradiography. A Coomassie-stained image of the autoradiograph is shown. The images are representative of triplicate experiments. Error bars indicate +SD, gene expression levels are shown relative to HPRT/Hprt. Scale bar: 5 μm (A, right, and D, right); 50 μm (A, left, and D, left); 250 μm (C); magnification in (C); ×11.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts